Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010
Mon, January 4, 2010
[ Mon, Jan 04th 2010 ] - Market Wire
Cordani Becomes CIGNA CEO
Thu, December 31, 2009
[ Thu, Dec 31st 2009 ] - Market Wire
Quit the Board
Wed, December 30, 2009
Tue, December 29, 2009
Mon, December 28, 2009
Thu, December 24, 2009
Wed, December 23, 2009
Tue, December 22, 2009
Mon, December 21, 2009
Fri, December 18, 2009

ImmuCell Hires Director of Sales and Marketing


//health-fitness.news-articles.net/content/2010/ .. ucell-hires-director-of-sales-and-marketing.html
Published in Health and Fitness on Monday, January 4th 2010 at 11:30 GMT by Market Wire   Print publication without navigation


PORTLAND, ME--(Marketwire - January 4, 2010) - ImmuCell Corporation (NASDAQ: [ ICCC ]) today announced the hiring of Bobbi Jo Kunde as Director of Sales and Marketing.

Ms. Kunde is a graduate of Iowa State University. After several positions with advertising and marketing firms, she joined APC, Inc. of Ankeny, Iowa in 1999. After serving first as its Marketing Manager and then Sales Manager, she was promoted to Director of Sales - East for APC's Calf Operations Group in 2008, in which position she served until December 2009.

"I am very pleased to welcome Bobbi to the ImmuCell team," commented Michael F. Brigham, President and CEO. "I am convinced that this is a significant milestone for ImmuCell."

Ms. Kunde is well known in the dairy industry. Her accomplishments include some significant product launches of serum-based colostrum supplement and replacer products. ImmuCell sees a real opportunity to benefit from this new hire and from ongoing product development efforts to grow its business to the next level.

"I am very excited to be joining such a customer focused team that is committed to assuring exceptional product quality. What ImmuCell has accomplished to date with limited sales and marketing resources speaks to the products' performance and the tenacity of the team," explained Bobbi Jo Kunde, Director of Sales and Marketing. "I will be building on this foundation and am committed to being a valuable asset to dairy and beef producers, our distribution chain, and ImmuCell stockholders."

Ms. Kunde's home office is located in Wisconsin, a leading dairy state with over 1,200,000 dairy cows on nearly 13,000 dairy farms.

Brian E. Sturgeon, Sales Manager, will report to Ms. Kunde, continuing in the same role that he has served for the past six years. By building upon Mr. Sturgeon's successful efforts in the field and adding Ms. Kunde to the Company's sales and marketing efforts, ImmuCell is positioning itself to further grow the sales of current products as well as First Defense® line extensions and other new products.

ImmuCell Corporation is a biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at [ http://www.immucell.com ]. ImmuCell's lead product, First Defense®, is the only USDA-licensed, orally delivered scours preventative product on the market for calves with claims against E. coli K99 and coronavirus infections.

Forward-Looking Statement Disclaimer:

The foregoing press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as, but not limited to, our success at achieving our business growth objectives and launching new products. Factors that could cause the Company's future results to differ materially from those described in the forward-looking statements, together with other risk factors, are detailed from time to time in filings we make with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Forward-looking statements in this press release are based on our current information and expectations. Actual results may differ materially due to various factors, including those risks.


Publication Contributing Sources